Sintilimab combined with anlotinib exhibited favorable antitumor activity and tolerable toxicity in post‐anti‐PD‐(L)1 therapy of metastatic NSCLC patients, supporting further randomized controlled trials. This evidence concerns the gene CD274 and non-small cell lung carcinoma.